A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes.
Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intestinal mucosa and released in response to a meal, is essential for normal glucose homoeostasis. There is much interest in the use of GLP-1 to treat diabetes, since the risk of hypoglycaemia is thought to be low. We report an instance of a 45-year-old woman with a GLP-1 and somatostatin secreting neuroendocrine tumour who presented with reactive hypoglycaemia and hyperglycaemia, but who was subsequently cured by surgery. This case, of a neuroendocrine tumour secreting GLP-1 and causing reactive hypoglycaemia, indicates a potential adverse effect of GLP-1 therapy for diabetes.
Todd
J F
JF
Endocrine Unit, Imperial College Faculty of Medicine, Hammersmith Hospital, W12 ONN, London, UK. jeanie.todd@ic.ac.uk
Stanley
S A
SA
Roufosse
C A
CA
Bishop
A E
AE
Khoo
B
B
Bloom
S R
SR
Meeran
K
K
D001786:Blood Glucose; D002276:Carcinoid Tumor / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D048909:Diabetes Complications; D005260:Female; D005934:Glucagon / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D005951:Glucose Tolerance Test; D006801:Humans; D007003:Hypoglycemia / Q000150:complications; D007044:Hysterectomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D010446:Peptide Fragments / Q000378:metabolism*; D011498:Protein Precursors / Q000378:metabolism*; D013004:Somatostatin / Q000378:metabolism*
D001786:Blood Glucose; D010446:Peptide Fragments; D011498:Protein Precursors; D013004:Somatostatin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon